Last reviewed · How we verify
adjuvanted Arepanrix
Arepanrix is an adjuvanted pandemic influenza vaccine that stimulates immune response against H1N1 influenza virus through a combination of viral antigen and an immune-enhancing adjuvant.
Arepanrix is an adjuvanted pandemic influenza vaccine that stimulates immune response against H1N1 influenza virus through a combination of viral antigen and an immune-enhancing adjuvant. Used for Pandemic H1N1 influenza prevention (2009 H1N1 pandemic strain).
At a glance
| Generic name | adjuvanted Arepanrix |
|---|---|
| Also known as | Influenza vaccine |
| Sponsor | University of British Columbia |
| Drug class | Adjuvanted inactivated influenza vaccine |
| Target | H1N1 influenza virus hemagglutinin and neuraminidase antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated H1N1 influenza virus antigen combined with AS03, an oil-in-water adjuvant containing squalene, alpha-tocopherol, and polysorbate 80. The adjuvant enhances and accelerates the body's immune response to the viral antigen, promoting both humoral (antibody) and cellular immunity against H1N1 influenza. This formulation allows for dose-sparing while maintaining immunogenicity.
Approved indications
- Pandemic H1N1 influenza prevention (2009 H1N1 pandemic strain)
Common side effects
- Injection site reactions (pain, redness, swelling)
- Myalgia
- Headache
- Fatigue
- Fever
Key clinical trials
- Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years (PHASE2)
- Risk of Narcolepsy Associated With Administration of H1N1 Vaccine
- Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children (PHASE4)
- Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine
- Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- adjuvanted Arepanrix CI brief — competitive landscape report
- adjuvanted Arepanrix updates RSS · CI watch RSS
- University of British Columbia portfolio CI